Advertisement

High-dose Dual Therapy Is Superior to Standard First-line or Rescue Therapy for Helicobacter pylori Infection

Published:November 14, 2014DOI:https://doi.org/10.1016/j.cgh.2014.10.036

      Background & Aims

      The efficacy of treatment of Helicobacter pylori infection has decreased steadily because of increasing resistance to clarithromycin, metronidazole, and levofloxacin. Resistance to amoxicillin is generally low, and high intragastric pH increases the efficacy of amoxicillin, so we investigated whether a combination of a high-dose proton pump inhibitor and amoxicillin (dual therapy) was more effective than standard first-line or rescue therapies in eradicating H pylori.

      Methods

      We performed a large-scale multihospital trial to compare the efficacy of a high-dose dual therapy (HDDT) with that of standard therapies in treatment-naive (n = 450) or treatment-experienced (n = 168) patients with H pylori infection. Treatment-naive patients were randomly assigned to groups given HDDT (rabeprazole 20 mg and amoxicillin 750 mg, 4 times/day for 14 days, group A1), sequential therapy for 10 days (group B1), or clarithromycin-containing triple therapy for 7 days (group C1). Treatment-experienced patients were randomly assigned to groups given HDDT for 14 days (group A2), sequential therapy for 10 days (B2), or levofloxacin-containing triple therapy for 7 days (C2). H pylori infection was detected by using the 13C-urea breath test. We evaluated factors associated with treatment outcomes.

      Results

      In the intention-to-treat analysis, H pylori was eradicated in 95.3% of patients in group A1 (95% confidence interval [CI], 91.9%−98.8%), 85.3% in B1 (95% CI, 79.6%−91.1%), and 80.7% in group C1 (95% CI, 74.3%−87.1%). Infection was eradicated in 89.3% of patients in group A2 (95% CI, 80.9%−97.6%), 51.8% in group B2 (95% CI, 38.3%−65.3%), and 78.6% (95% CI, 67.5%−89.7%) in group C2. The efficacy of HDDT was significantly higher than that of currently recommended regimens, irrespective of CYP2C19 genotype. Bacterial resistance to drugs was associated with treatment failure. There were no significant differences between groups in adverse events or patient adherence.

      Conclusions

      HDDT is superior to standard regimens as empirical first-line or rescue therapy for H pylori infection, with similar safety profiles and tolerability. ClinicalTrials.gov number: NCT01163435.

      Keywords

      Abbreviations used in this paper:

      AMO (amoxicillin), 13C-UBT (13C-urea breath test), CI (confidence interval), CLA-TT (clarithromycin-containing triple therapy), HDDT (high-dose dual therapy), ITT (intention-to-treat), LEV-TT (levofloxacin-containing triple therapy), MIC (minimum inhibitory concentration), MTZ (metronidazole), PP (per-protocol), PPI (proton pump inhibitor), ST (sequential therapy)
      To read this article in full you will need to make a payment
      AGA Member Login
      Login with your AGA username and password.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • McColl K.E.L.
        Helicobacter pylori infection.
        N Engl J Med. 2010; 362: 1597-1604
        • Malfertheiner P.
        • Megraud F.
        • O'Morain C.A.
        • et al.
        Management of Helicobacter pylori infection: the Maastricht IV/Florence Consensus Report.
        Gut. 2012; 61: 646-664
        • Chey W.D.
        • Wong B.C.Y.
        Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection.
        Am J Gastroenterol. 2007; 102: 1808-1825
        • Fock K.M.
        • Katelaris P.
        • Sugano K.
        • et al.
        Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection.
        J Gastroenterol Hepatol. 2009; 24: 1587-1600
        • Graham D.Y.
        • Fischbach L.
        Helicobacter pylori treatment in the era of increasing antibiotic resistance.
        Gut. 2010; 59: 1143-1153
        • Vakil N.
        • Vaira D.
        Treatment for H. pylori infection: new challenges with antimicrobial resistance.
        J Clin Gastroenterol. 2013; 47: 383-388
        • Heep M.
        • Kist M.
        • Strobel S.
        • et al.
        Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy.
        Eur J Clin Microbiol Infect Dis. 2000; 19: 538-541
        • Peitz U.
        • Sulliga M.
        • Wolle K.
        • et al.
        High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study.
        Aliment Pharmacol Ther. 2002; 16: 315-324
        • Glupczynski Y.
        • Megraud F.
        • Lopez-Brea M.
        • et al.
        European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori.
        Eur J Clin Microbiol Infect Dis. 2001; 20: 820-823
        • Meyer J.M.
        • Silliman N.P.
        • Wang W.
        • et al.
        Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999.
        Ann Intern Med. 2002; 136: 13-24
        • Berry V.
        • Jennings K.
        • Woodnutt G.
        Bactericidal and morphological effects of amoxicillin on Helicobacter pylori.
        Antimicrob Agents Chemother. 1995; 39: 1859-1861
        • Craig W.A.
        Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.
        Clin Infect Dis. 1998; 26: 1-12
        • Yang J.C.
        • Lin C.J.
        CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection.
        Expert Opin Drug Metab Toxicol. 2010; 6: 29-41
        • Yang J.C.
        • Yang K.C.
        • Hsu C.T.
        • et al.
        A multicenter study on eradication of Helicobacter pylori infection in patients with duodenal ulcer by lansoprazole-antibiotics combined therapy.
        J Microbiol Immunol Infect. 1999; 32: 1-8
        • Gisbert J.P.
        • Morena F.
        Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure.
        Aliment Pharmacol Ther. 2006; 23: 35-44
        • Yang J.C.
        • Lu C.W.
        • Lin C.J.
        Treatment of Helicobacter pylori infection: current status and future concepts.
        World J Gastroenterol. 2014; 20: 5283-5293
        • Greenberg E.R.
        • Anderson G.L.
        • Morgan D.R.
        • et al.
        14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
        Lancet. 2011; 378: 507-514
        • Hunt R.H.
        pH and Hp: gastric acid secretion and Helicobacter pylori—implications for ulcer healing and eradication of the organism.
        Am J Gastroenterol. 1993; 88: 481-483
        • Bayerdorffer E.
        • Miehlke S.
        • Mannes G.A.
        • et al.
        Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers.
        Gastroenterology. 1995; 108: 1412-1417
        • Agrawal A.
        • Tutuian R.
        • Hila A.
        • et al.
        Ingestion of acidic foods mimics gastroesophageal reflux during pH monitoring.
        Dig Dis Sci. 2005; 50: 1916-1920
        • Kawakami Y.
        • Akahane T.
        • Yamaguchi M.
        • et al.
        In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori.
        Antimicrob Agents Chemother. 2000; 44: 458-461
        • Yang J.C.
        • Wang H.L.
        • Chern H.D.
        • et al.
        Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication.
        Pharmacotherapy. 2011; 31: 227-238
        • Sugimoto M.
        • Furuta T.
        • Shirai N.
        • et al.
        Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status.
        Clin Pharmacol Ther. 2004; 76: 290-301
        • Furuta T.
        • Shirai N.
        • Takashima M.
        • et al.
        Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin.
        Pharmacogenetics. 2001; 11: 341-348
        • Megraud F.
        • Coenen S.
        • Versporten A.
        • et al.
        Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption.
        Gut. 2013; 62: 34-42
        • Rimbara E.
        • Noguchi N.
        • Kawai T.
        • et al.
        Mutations in penicillin-binding proteins 1, 2 and 3 are responsible for amoxicillin resistance in Helicobacter pylori.
        J Antimicrob Chemother. 2008; 61: 995-998
        • Jafri N.S.
        • Homung C.A.
        • Howden C.W.
        Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naïve to treatment.
        Ann Intern Med. 2008; 148: 923-931
        • Fuccio L.
        • Minardi M.E.
        • Zagari R.M.
        • et al.
        Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication.
        Ann Intern Med. 2007; 147: 553-562
        • Zagari R.M.
        • Bianchi-Porro G.
        • Fiocca R.
        • et al.
        Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study.
        Gut. 2007; 56: 475-479
        • Megraud F.
        • Lehours P.
        Helicobacter pylori delection and antimicrobial susceptibility testing.
        Clin Microbiol Rev. 2007; 20: 280-322
        • Liou J.M.
        • Chen C.C.
        • Chen M.J.
        • et al.
        Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
        Lancet. 2013; 381: 205-213
        • Hsu P.I.
        • Wu D.C.
        • Wu J.Y.
        • et al.
        Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days?.
        Helicobacter. 2011; 16: 146-152

      References

        • Dixon M.F.
        • Genta R.M.
        • Yardley J.H.
        • et al.
        Classification and grading of gastritis: the updated Sydney System—International Workshop on the Histopathology of Gastritis, Houston 1994.
        Am J Surg Pathol. 1996; 20: 1161-1181
        • Yang J.C.
        • Yang K.C.
        • Hsu C.T.
        • et al.
        A multicenter study on eradication of Helicobacter pylori infection in patients with duodenal ulcer by lansoprazole-antibiotics combined therapy.
        J Microbiol Immunol Infect. 1999; 32: 1-8
        • Lin C.J.
        • Yang J.C.
        • Uang Y.S.
        • et al.
        Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers.
        Pharmacotherapy. 2003; 23: 711-719
        • de Morais S.M.
        • Wilkinson G.R.
        • Blaisdell J.
        • et al.
        Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese.
        Mol Pharmacol. 1994; 46: 594-598
        • de Morais S.M.
        • Wilkinson G.R.
        • Blaisdell J.
        • et al.
        The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.
        J Biol Chem. 1994; 269: 15419-15422
        • di Giovine F.S.
        • Takhsh E.
        • Blakemore A.I.
        • et al.
        Single base polymorphism at -511 in the human interleukin-1β gene (IL 1β).
        Hum Mol Genet. 1992; 1: 450